Advice

Recommended for restricted use within NHS Scotland.

RECOMMENDATION

Bexarotene is recommended for use in Scotland as a second line treatment for patients with advanced (stages IIb or III) cutaneous T-cell lymphoma. Bexarotene treatment should normally be initiated and supervised by haematologists, dermatologists or oncologists and used for patients who have proved refractory both to local skin directed therapy and to at least one systemic treatment.

Download detailed advice18KB (PDF)

Download

Medicine details

Medicine name:
Bexarotene (Targretin®)
SMC ID:
14/02
Indication:
Skin manifestations of advanced stage cutaneous T-cell lymphoma
Pharmaceutical company
Ligland/Elan
BNF chapter
Malignant disease and immunosuppression
Submission type
Full
Status
Restricted
Date advice published
08 November 2002